Alvotech Stock Forecast
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:15 PM ET
ALVO analyst consensus
Consensus (7 analysts)
none
Avg. price target
$6.80+18.49%
- Strong buy 2
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Alvotech (2026-10-07), 6 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $6.80, with a high estimate of $9.00 and a low estimate of $4.00. The average target implies upside of 18.5% from the current price of $5.74.
The spread between the highest and lowest targets is 125.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALVO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 29% |
| Buy | 4 | 57% |
| Hold | 1 | 14% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | -30.30% |
| Average target | $6.80 | +18.49% |
| High target | $9.00 | +56.83% |